Financial PerformanceManagement reiterated strong confidence in both accelerating obesity franchise demand prospects and the company’s pipeline.
Market PositionOrforglipron's shorter timeline to market compared to AZD5004 suggests a competitive advantage for Eli Lilly.
Product DevelopmentMuvalaplin, Eli Lilly's oral Lp(a) candidate, demonstrated up to 85.8% reduction in Lp(a) levels in adults, which is competitive with injectable therapies.